RemeGen
Chinese biotech selling telitacicept and disitamab vedotin, now profitable.
On the record
Checkpoint: Vor Bio global Phase 3 readouts for telitacicept in gMG and Sjogren's disease
The call
RemeGen now profits from five approved telitacicept indications while disitamab vedotin's global upside depends on Vor Bio's untested Phase 3 program.
RemeGen is a Chinese drug company that has already brought two main medicines to market: telitacicept (approved for five diseases) and disitamab vedotin (a cancer drug sold in China). The company is now making money, which is a big milestone. However, disitamab vedotin now faces real competition from Enhertu, a similar drug made by Pfizer and AstraZeneca that is losing market share (Pfizer took a $1.6 billion loss on it in late 2024). The bigger uncertainty is that RemeGen's biggest future growth depends on its partner Vor Bio successfully running late-stage trials in the United States, Europe, and Japan for two new diseases, which is not guaranteed. One change that could shift the story: if Vor Bio's trials fail, or if Chinese pricing regulators cut telitacicept's price sharply, the company's growth picture would shrink significantly.
Why
01
AI pressure: AI-native drug discovery platforms like Insilico Medicine. AI-driven discovery could let rivals design faster BAFF/APRIL or HER2 drugs, pressuring RemeGen's next pipeline wave, not its approved drugs. Could AI do the core job? Unlikely.
02
Bigger players: AstraZeneca/Daiichi Sankyo's Enhertu (HER2 ADC). Enhertu already crowds disitamab vedotin abroad; Pfizer wrote down $1.6bn on the drug in Q4 2025 alone. Could a giant copy it? No, they are blocked.
03
What protects it. Five NMPA-approved indications, China manufacturing, and NRDL reimbursement access keep telitacicept's home market hard to copy.
What would change this call
Vor Bio reports Phase 3 readout for telitacicept in gMG or Sjogren's disease. Would show whether the >$4bn ex-China licensing deal has a viable path to approval.
Pfizer discloses another write-down or de-emphasis of disitamab vedotin. Would confirm continued loss of ex-China ADC market share to Enhertu.
NRDL announces reimbursement price changes for telitacicept in China. Would show whether domestic pricing pressure is compressing RemeGen's core margin.
Pfizer discloses another write-down or de-emphasis of disitamab vedotin. Would confirm continued loss of ex-China ADC market share to Enhertu.
NRDL announces reimbursement price changes for telitacicept in China. Would show whether domestic pricing pressure is compressing RemeGen's core margin.
Key numbers
- FY2025 revenue ~RMB3.25bn, up 89% YoY
- FY2025 net profit ~RMB716m, first full profitable year
- Telitacicept sold >1.5M doses in 2024
Named risks
- Vor Bio's global Phase 3 trials in gMG and Sjogren's disease could fail, eliminating most of the over $4bn deal upside.
- Further Pfizer write-downs on disitamab vedotin amid Enhertu competition could shrink ex-China royalty stream.
- NRDL pricing renegotiation could pressure telitacicept margins in China.
- Stock volatility (52-week range HK$57.65 to HK$126.60, -19.3% in 30 days as of July 20, 2026) signals investor uncertainty.
- AI-native discovery platforms could compress future pipeline development timelines for competitors.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| AstraZeneca/Daiichi Sankyo (Enhertu) | losing to | Pfizer wrote down $1.6bn on disitamab vedotin citing Enhertu competition, Feb 3, 2026 |
| Pfizer (Seagen) | contesting | Pfizer holds ex-China disitamab vedotin rights but recorded $1.8bn cumulative impairments 2024 to Q4 2025 |
| GSK Benlysta (belimumab) | contesting | Closest mechanistic BAFF-inhibitor analog to telitacicept in autoimmune disease market |
| Jiangsu Hengrui Pharmaceuticals | contesting | Hengrui has 31 pipeline ADCs versus RemeGen's narrower ADC portfolio, per May 9, 2026 analysis |
| Akeso Inc. | contesting | Chinese HK-listed immuno-oncology peer with ~3,761 employees versus RemeGen's ~3,048 |
| Insilico Medicine (AI-native discovery) | gaining on | Cited as comparable peer with faster in-silico pipeline timelines, July 14, 2026 profile |
Questions people ask
- Is RemeGen profitable in 2026?
- Yes. RemeGen reported FY2025 net profit attributable to owners of about RMB716m, its first full profitable year, on total operating revenue of roughly RMB3.25bn, up 89.36% year over year, per its February 27, 2026 annual results update announcement.
- What is RemeGen's biggest competitive threat?
- Enhertu, the HER2 ADC from AstraZeneca and Daiichi Sankyo, is squeezing RemeGen's disitamab vedotin outside China. Pfizer, which holds ex-China rights via Seagen, recorded a $200m impairment in 2024 plus a further $1.6bn write-down in Q4 2025 citing Enhertu competition, as of February 3, 2026.
- Could AI replace RemeGen's drug pipeline?
- Not the approved drugs. Telitacicept and disitamab vedotin are NMPA-approved, commercialized, backed by completed Phase 3 data and NRDL listing, moats AI cannot bypass. AI-native discovery platforms like Insilico Medicine are a longer-term watch item for future pipeline speed, not current revenue, per a July 14, 2026 FT Markets profile.
- Is joining RemeGen a safe career move?
- Reasonably defensible: RemeGen turned its first full-year profit in FY2025 (RMB716m net profit) and had about 3,048 employees as of December 31, 2025, up 1.63% year over year. Risk centers on a binary Vor Bio Phase 3 catalyst and Pfizer's ongoing $1.6bn disitamab vedotin write-downs disclosed February 2026.
- Who owns RemeGen and where is it listed?
- RemeGen is a publicly traded, PRC-incorporated joint-stock company with no controlling parent identified. It dual-lists as H-shares on Hong Kong Exchange (9995.HK) since November 2020 and A-shares on Shanghai's STAR Market (688331.SH) since March 2022.
- What is the Vor Bio deal with RemeGen worth?
- In June 2025, Vor Bio licensed ex-Greater-China rights to telitacicept in a deal potentially worth over $4bn total: $45m upfront cash, $80m in warrants, plus milestones and royalties, contingent on Vor Bio's ongoing global Phase 3 trials in gMG and Sjogren's disease.
Timeline
- 2026-06-08NMPA conditionally approves telitacicept for IgA nephropathy, its 4th China indication
- 2026-06-08NMPA approves telitacicept for Sjogren's disease, its 5th China indication
- 2026-05-14TELIGAN Phase 3 results published in NEJM showing 55% placebo-adjusted proteinuria reduction
- 2026-02-272025 annual results update: revenue ~RMB3.25bn (+89.36% YoY), net profit ~RMB716m
- 2026-02-03Pfizer discloses further $1.6bn write-down on disitamab vedotin citing Enhertu competition
- 2026-01-30Estimated 2025 annual results filed showing FY2024 revenue comparison of RMB1,716.86m
- 2025-06-25Vor Bio signs exclusive global license for telitacicept, deal potentially worth over $4bn
- 2022-03RemeGen completes Shanghai A-share IPO on STAR Market, raising ~RMB2.6bn
- 2020-11RemeGen completes Hong Kong IPO (9995.HK), raising ~HK$3.99bn to HK$4.59bn
- 2008-07-04RemeGen founded by Dr. Jianmin Fang and Wang Weidong in Yantai, Shandong
Revision history
26 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- 2025 Annual Results Update Announcement (2026-02-27)
- Estimated 2025 Annual Results (2026-01-30)
- RemeGen Boosts 2025 Revenue as Telitacicept Wins New Approvals and NRDL Access (2026-03-27)
- Vor Bio's surprise $4B revival deal splits investor reactions (2025-06-26)
- RemeGen Co. Ltd. Company Profile & Executives - WSJ
- O'Melveny Represents RemeGen in World's Largest BioPharma Primary Listing and IPO of 2020 (2020-11-09)
- O'Melveny Represents RemeGen in its A-share IPO and Listing on SSE STAR Market (2022-03-31)
- wikipedia.org (2026-07-26)
- Telitacicept Receives NMPA Conditional Approval for IgAN (2026-06-08)
- Telitacicept Receives NMPA Approval for Sjögren's Disease (2026-06-08)
- Vor Bio Announces Publication of Interim Analysis of TELIGAN (2026-05-14)
- Vor Bio Enters into Exclusive Global License Agreement with RemeGen (2025-06-25)